This company has been acquired
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
CNCE Overzicht aandelen
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 0/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
Concert Pharmaceuticals, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$8.37 |
| 52 Week Hoogtepunt | US$8.55 |
| 52 Week Laag | US$2.66 |
| Bèta | 0.52 |
| 11 maand verandering | 0% |
| 3 maanden verandering | 92.86% |
| 1 Jaar Verandering | 203.26% |
| 33 jaar verandering | -9.22% |
| 5 jaar verandering | -64.31% |
| Verandering sinds IPO | -40.97% |
Recent nieuws en updates
Recent updates
Is Concert Pharmaceuticals (NASDAQ:CNCE) In A Good Position To Invest In Growth?
Jan 22
CinCor Pharma hits 52-week high on data for antihypertensive agent
Aug 08Concert Pharmaceuticals: A Balanced Risk/Reward
Jun 15We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate
Jun 04Concert Pharmaceuticals: A Speculative Buy For Their Alopecia Areata Drug
Jun 03Concert Pharmaceuticals (NASDAQ:CNCE) Is In A Good Position To Deliver On Growth Plans
Jan 11Here's Why We're Watching Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation
Aug 27We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate
May 25Concert Pharma EPS beats by $0.02
May 04Concert Pharmaceuticals' (NASDAQ:CNCE) Stock Price Has Reduced 70% In The Past Three Years
Feb 27Concert Pharma fails in mid-stage study for CTP-692 Schizophrenia
Feb 01Here's Why We're Not Too Worried About Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation
Jan 23How Much Of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Do Insiders Own?
Dec 19
A Look At Concert Pharmaceuticals' (NASDAQ:CNCE) Share Price Returns
Nov 23Concert Pharma EPS beats by $0.15
Nov 05Concert Pharma launches late-stage study of CTP-543 in hair loss disorder
Nov 03Rendement voor aandeelhouders
| CNCE | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | -0.1% | 0.6% | 0.8% |
| 1Y | 203.3% | 27.4% | 38.4% |
Rendement versus industrie: CNCE exceeded the US Biotechs industry which returned 8.9% over the past year.
Rendement versus markt: CNCE exceeded the US Market which returned -5.5% over the past year.
Prijsvolatiliteit
| CNCE volatility | |
|---|---|
| CNCE Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stabiele aandelenkoers: CNCE's share price has been volatile over the past 3 months.
Volatiliteit in de loop van de tijd: CNCE's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2006 | 64 | Roger Tung | www.concertpharma.com |
Concert Pharmaceuticals, Inc. Samenvatting
| CNCE fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$520.71m |
| Inkomsten(TTM) | -US$126.68m |
| Inkomsten(TTM) | US$32.04m |
16.3x
P/S-verhouding-4.1x
Koers/WinstverhoudingIs CNCE overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| CNCE resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$32.04m |
| Kosten van inkomsten | US$102.70m |
| Brutowinst | -US$70.66m |
| Overige uitgaven | US$56.02m |
| Inkomsten | -US$126.68m |
Laatst gerapporteerde inkomsten
Sep 30, 2022
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -2.04 |
| Brutomarge | -220.53% |
| Nettowinstmarge | -395.36% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde CNCE op de lange termijn?
Bekijk historische prestaties en vergelijking